Immunogenicity of Mepolizumab in Patients with Severe Eosinophilic Asthma: Experience from the Clinical Development Program

H. Ortega (La Jolla, CA, United States of America), E. Meyer (Philadelphia, PA, United States of America), G. Brusselle (Ghent, Belgium), K. Asano (Kanagawa, Japan), R. Price (Stevenage, Hertfordshire, United Kingdom), C. Prazma (Research Triangle Park, NC, United States of America), F. Albers (Research Triangle Park, NC, United States of America), S. Yancey (Research Triangle Park, NC, United States of America), G. Gleich (Utah, United States of America)

Source: International Congress 2018 – Novel immunology-based therapies in asthma and COPD
Session: Novel immunology-based therapies in asthma and COPD
Session type: Oral Presentation
Number: 1650
Disease area: Airway diseases

Congress or journal article abstractWebcastSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
H. Ortega (La Jolla, CA, United States of America), E. Meyer (Philadelphia, PA, United States of America), G. Brusselle (Ghent, Belgium), K. Asano (Kanagawa, Japan), R. Price (Stevenage, Hertfordshire, United Kingdom), C. Prazma (Research Triangle Park, NC, United States of America), F. Albers (Research Triangle Park, NC, United States of America), S. Yancey (Research Triangle Park, NC, United States of America), G. Gleich (Utah, United States of America). Immunogenicity of Mepolizumab in Patients with Severe Eosinophilic Asthma: Experience from the Clinical Development Program. 1650

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: